Co-Authors
This is a "connection" page, showing publications co-authored by JIUN-KAE JACK LEE and VASSILIKI A PAPADIMITRAKOPOULOU.
Connection Strength
1.662
-
The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett. 2006 Jul 28; 239(1):136-43.
Score: 0.276
-
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80.
Score: 0.135
-
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14.
Score: 0.092
-
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41.
Score: 0.092
-
Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21.
Score: 0.087
-
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6.
Score: 0.087
-
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009 Feb 01; 27(4):599-604.
Score: 0.086
-
Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008 Apr 01; 14(7):2095-101.
Score: 0.082
-
Akt activation correlates with adverse outcome in tongue cancer. Cancer. 2005 Dec 01; 104(11):2430-6.
Score: 0.070
-
Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer. 2005 Mar 01; 103(5):952-9.
Score: 0.066
-
Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12):1605-10.
Score: 0.057
-
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53.
Score: 0.055
-
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 2000 May; 6(5):1702-10.
Score: 0.047
-
Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Cancer J Sci Am. 1997 Mar-Apr; 3(2):92-9.
Score: 0.038
-
Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst. 1997 Feb 05; 89(3):257-8.
Score: 0.038
-
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8.
Score: 0.029
-
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
Score: 0.027
-
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
Score: 0.026
-
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
Score: 0.026
-
Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011 Feb; 4(2):218-29.
Score: 0.025
-
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila). 2010 Jul; 3(7):800-9.
Score: 0.024
-
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
Score: 0.024
-
DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009 Oct 01; 15(19):6284-91.
Score: 0.023
-
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008 Jan 20; 26(3):354-60.
Score: 0.020
-
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
Score: 0.018
-
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97.
Score: 0.018
-
Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res. 2006 May 15; 12(10):3109-14.
Score: 0.018
-
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
Score: 0.015
-
Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst. 2003 Feb 05; 95(3):198-205.
Score: 0.014
-
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
Score: 0.014
-
Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst. 2000 Jan 05; 92(1):69-73.
Score: 0.012
-
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998 Oct 21; 90(20):1545-51.
Score: 0.011
-
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Apr; 16(4):1325-30.
Score: 0.010